A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is application/pdf.
Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib
2008
Molecular Cancer Therapeutics
Preserved Fulltext
Medullary thyroid carcinoma (MTC) is an uncommon malignancy of hereditary and sporadic presentation. Mutations in the RET proto-oncogene are involved in the pathogenesis of familial MTC and >50% of the sporadic cases. Currently, there is no effective treatment for recurrent or metastatic MTC. We report here a rapid response to a sorafenib (RET and RAF kinase and vascular endothelial growth factor receptor inhibitor) -based regimen in a patient with sporadic MTC who had advanced, progressive
doi:10.1158/1535-7163.mct-07-2422
pmid:18445656
fatcat:ljitdiovzrfl7gy7vid5pirnli